Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drugs induced osteopathies].

Bérengère Aubry-Rozier1

  • 1Service de rhumatologie et Centre des maladies osseuses, Département de l'appareil locomoteur, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|July 19, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung function in adult patients with osteogenesis imperfecta: a cohort study.

Orphanet journal of rare diseases·2024
Same author

Functional neurological signs in hypermobile Ehlers-Danlos syndrome and hypermobile spectrum disorders with suspected neuropathic pain.

Brain and behavior·2024
Same author

Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study.

Bone·2023
Same author

A novel approach for fibrous dysplasia assessment using combined planar and quantitative SPECT/CT analysis of Tc-99m-diphosphonate bone scan in correlation with biological bone turnover markers of disease activity.

Frontiers in medicine·2022
Same author

Small fiber neuropathy in hypermobile Ehlers Danlos syndrome/hypermobility spectrum disorder.

Journal of internal medicine·2022
Same author

Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?

Rheumatology international·2021

This study examines how iron replacement, proton pump inhibitors, and certain antidepressants can cause bone diseases like osteoporosis and osteomalacia. It details mechanisms and offers prevention strategies for these commonly used medications.

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Endocrinology

Background:

  • Drug-induced bone diseases are a significant concern, encompassing osteoporosis, osteomalacia, and sarcopenia.
  • While some drugs like corticotherapy are well-known causes, others like iron replacement, proton pump inhibitors (PPIs), and serotonin reuptake inhibitors (SRIs) are less recognized but frequently used.

Purpose of the Study:

  • To investigate the less-known drug-induced bone diseases caused by iron replacement, PPIs, and SRIs.
  • To elucidate the pathophysiological mechanisms linking these drugs to bone fragility.
  • To provide recommendations for the prevention and management of bone-related adverse effects.

Main Methods:

  • Literature review and analysis of pathophysiological pathways.
  • Examination of clinical data and case studies related to drug-induced bone diseases.

Related Experiment Videos

  • Synthesis of current evidence to formulate management guidelines.

    • Main Results:

    • Iron replacement therapy can lead to bone density loss through various mechanisms.
    • Proton pump inhibitors are associated with altered calcium and vitamin D absorption, impacting bone health.
    • Serotonin reuptake inhibitors may affect bone remodeling and increase fracture risk.

    Conclusions:

    • Iron replacement, PPIs, and SRIs represent important iatrogenic causes of bone disease.
    • Understanding the specific mechanisms is crucial for clinical practice.
    • Proactive monitoring and management strategies are necessary to mitigate bone fragility in patients on these medications.